{"entity":{"id":"nct03091192","kind":"trial","name":"Savolitinib vs. Sunitinib in MET-driven PRCC.","aka":[],"tldr":"A phase 3 trial of Savolitinib and Sunitinib in renal cell carcinoma, run by AstraZeneca, active and no longer recruiting.","summary":"Savolitinib vs. Sunitinib in MET-driven PRCC. is a phase 3 interventional study registered as NCT03091192 by AstraZeneca, with 60 participants enrolled, started 2017-07-25 and due to reach its primary completion in 2019-08-18. Interventions recorded: Savolitinib and Sunitinib. Results have been posted on the registry.","status":"active","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT03091192","url":"https://clinicaltrials.gov/study/NCT03091192"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["rcc","papillary-rcc"],"sections":[],"technologies":["antiangiogenic","kinase-inhibitors"],"targets":[],"drugs":["savolitinib","sunitinib"],"companies":["astrazeneca","hutchmed"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT03091192","phase":"3","setting":"A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib Versus Sunitinib in Patients With MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)","sponsor":"AstraZeneca","started":"2017-07-25","startedType":"actual","yearReported":2020,"enrolled":60,"enrolledBasis":"registry","outcomes":[{"endpoint":"Progression Free Survival (PFS) by Blinded Independent Central Review (BICR)","primary":true,"unit":"months","arms":[{"name":"Savolitinib QD","n":33,"value":7,"note":"95% CI 2.8 to NA; Figures from the ClinicalTrials.gov results section (first posted 2020-07-10), not from a publication"},{"name":"Sunitinib QD","n":27,"value":5.6,"note":"95% CI 4.1 to 6.9"}],"hr":0.71,"ci":[0.37,1.36],"p":"0.313","source":"https://clinicaltrials.gov/study/NCT03091192?tab=results"}]},"route":"/trials/nct03091192/","neighbours":{"cancer":[{"id":"papillary-rcc","kind":"cancer","name":"Papillary renal cell carcinoma","route":"/cancers/papillary-rcc/"},{"id":"rcc","kind":"cancer","name":"Renal cell carcinoma","route":"/cancers/rcc/"}],"technology":[{"id":"antiangiogenic","kind":"technology","name":"Anti-angiogenic therapy","route":"/technologies/antiangiogenic/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"savolitinib","kind":"drug","name":"Savolitinib","route":"/drugs/savolitinib/"},{"id":"sunitinib","kind":"drug","name":"Sunitinib","route":"/drugs/sunitinib/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"},{"id":"hutchmed","kind":"company","name":"Hutchmed","route":"/companies/hutchmed/"}],"target":[{"id":"prcc","kind":"target","name":"PRCC","route":"/targets/prcc/"}]}}